Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04383743 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT04383743 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 17 participants.
The verdict
NCT04383743, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This pilot study is evaluating how well pembrolizumab and combination chemotherapy before surgery work for the treatment of specific types of muscle-invasive bladder cancer that have unusual appearance (variants). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, vinblastine, adriamycin, and cisplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and combination chemotherapy before surgery may work better in treating patients with these muscle invasive bladder cancer variants compared to chemotherapy alone.
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Cisplatin
- DRUG Doxorubicin
- BIOLOGICAL Pegfilgrastim
- DRUG Methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2020-11-24 |
| Est. Completion | 2025-03-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04383743
The ClinicalTrials.gov registry entry for NCT04383743 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT04383743 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04383743 about?
NCT04383743 is a clinical study titled "Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer". This pilot study is evaluating how well pembrolizumab and combination chemotherapy before surgery work for the treatment of specific types of muscle-invasive bladder cancer that have unusual appearance (variants). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's i...
What is the current status of trial NCT04383743?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2020-11-24. Estimated completion is 2025-03-04.
What interventions are being tested in trial NCT04383743?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Cisplatin (DRUG), Doxorubicin (DRUG), Pegfilgrastim (BIOLOGICAL), Methotrexate (DRUG).
Who is sponsoring clinical trial NCT04383743?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.